Amoxicillin-Clavulanate Pediatric Dose — Otitis Media
Amoxicillin-clavulanate (Augmentin) is a beta-lactam/beta-lactamase inhibitor combination antibiotic that extends amoxicillin’s spectrum by protecting it from enzymatic degradation. It is widely used in pediatrics for the treatment of acute otitis media (AOM), particularly in cases involving beta-lactamase-producing organisms or multi-drug-resistant Streptococcus pneumoniae. Dosing references are based on the amoxicillin component.
Pediatric Dosing
Doses below refer to the amoxicillin component. The appropriate formulation ratio (e.g., 7:1 or 14:1) should be selected to deliver the target amoxicillin dose while minimizing unnecessary clavulanate exposure.
| Indication | Dose (amoxicillin component) | Frequency | Maximum |
|---|---|---|---|
| Standard AOM | 15–20 mg/kg PO | BID | 875 mg/dose |
| Multi-Drug-Resistant AOM | 40–45 mg/kg PO | BID | 875 mg/dose |
Worked example — standard dosing: For a 10 kg child: 10 × 15 mg/kg = 150 mg to 10 × 20 mg/kg = 200 mg per dose, given twice daily.
Worked example — MDR dosing: For a 10 kg child: 10 × 40 mg/kg = 400 mg to 10 × 45 mg/kg = 450 mg per dose, given twice daily. Maximum single dose: 875 mg regardless of weight.
Indications and Clinical Context
Amoxicillin-clavulanate is indicated for acute otitis media (AOM) when coverage against beta-lactamase-producing organisms such as Haemophilus influenzae or Moraxella catarrhalis is desired, or when initial amoxicillin therapy has failed. Per AAP guidelines, it is considered a first-line alternative in penicillin-allergic patients who can tolerate cephalosporins and is often preferred in children attending daycare or with recent antibiotic exposure, where resistant pathogens are more prevalent.
The higher-dose regimen (40–45 mg/kg/dose BID) is reserved for suspected or confirmed multi-drug-resistant organisms, including non-susceptible S. pneumoniae, where achieving higher pharmacodynamic targets (time above MIC) is clinically important. Formulary selection of the appropriate amoxicillin-to-clavulanate ratio is essential to avoid clavulanate-associated gastrointestinal adverse effects at elevated total daily doses.
Administration and Monitoring
Amoxicillin-clavulanate is administered orally as a suspension, chewable tablet, or tablet. The suspension should be refrigerated and shaken well before each dose. Administering with food reduces gastrointestinal intolerance, including diarrhea and nausea, which are the most common adverse effects. The maximum single dose is 875 mg; consult institutional protocol for total daily dose caps in higher-weight pediatric patients.
- Verify the correct formulation ratio to match the intended amoxicillin component dose.
- Monitor for diarrhea, rash (distinguish maculopapular rash from true IgE-mediated allergy), and signs of Clostridioides difficile infection with prolonged courses.
- Use with caution in patients with hepatic impairment given the clavulanate component; consult institutional protocol for dose adjustment guidance.
- Contraindicated in patients with a history of cholestatic jaundice or hepatic dysfunction associated with prior amoxicillin-clavulanate use.
Disclaimer: This article is an educational reference summarizing standard pediatric dosing values. It is not a substitute for clinical judgment. Always verify doses against institutional protocols, the current edition of authoritative references (e.g., Lexicomp, Harriet Lane Handbook, PALS guidelines), the patient’s accurate weight, and any patient-specific factors (renal/hepatic function, allergies, comedications) before administration.